Clinical trials: Influenza Prophylaxis
Upper Respiratory Infection
Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults
The purpose of the Study is to determine the prophylactic effects of CVT-E002 treatment for upper respiratory tract infections in healthy adult employees working with residents in continuing care facilities.
- Trial name
- NCT00259831
- Testing
- CVT-E002 (Cold-FX); a natural health product
- Where
- Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- CV Technologies
Influenza
A Randomised Controlled Trial on the Effect of Post-exposure Oseltamivir Prophylaxis on Influenza Transmission in Nursing Homes
The incidence of severe morbidity and mortality following an influenza infection during the annual influenza epidemics is highest among the elderly population and 90% of influenzaassociated mortality occurs in this group.
- Trial name
- PEPpIE (NCT01053377)
- Testing
- Tamiflu (verum)
- Where
- Netherlands
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Institute for Public Health and the Environment (RIVM)
Influenza Prevention, Seasonal Influenza
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
Background: Vaccines help the body learn to fight infections. Some vaccines are combined with adjuvants, which are added substances that make vaccines work better.
- Trial name
- NCT06863142
- Testing
- VRC-FLUMOS0116-00-VP, ALFQ
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention
One dose of escalating strengths of an investigational influenza vaccine VAX2012Q (Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine) will be evaluated for tolerability and immunogenicity in healthy adults 18-40…
- Trial name
- NCT02015494
- Testing
- VAX2012Q
- Where
- 4 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Influenza Prevention, Pandemic Influenza Prevention
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
Background: Influenza (flu) is a contagious respiratory illness caused by viruses. Flu symptoms can range from mild to severe, and the illness can be fatal. Vaccines help the body learn to prevent or fight infections such as flu.
- Trial name
- NCT07111078
- Testing
- VRC-FLUMOS0122-00-VP, ALFQ
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)
The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza…
- Trial name
- NCT01390792
- Testing
- Zanamivir hydrate
- Volunteers
- 622 people
- Sponsor
- GlaxoSmithKline
Healthy
A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus
This is a Phase I, parallel design open label study to evaluate safety, tolerability and immunogenicity of nine different formulation of two individual H1 and one H5 HA plasmid administered intradermally followed by…
- Trial name
- NCT01405885
- Testing
- INO-3605, INO-3609, INO-3401
- Where
- 3 sites in United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Haemophilus Influenzae Infection, Vaccines
Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b
Trial purpose is to evaluate the safety, tolerability and reactogenicity of the Vaccine for the prevention of infections caused by Haemophilus Influenzae Type b in volunteers aged 18-50.
- Trial name
- NCT05401305
- Testing
- Vaccine for the prevention of infections caused by Haemophilus influenza type b
- Where
- Russia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Influenza Prophylaxis
Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe
The primary objective of this study was to evaluate if administration of a seasonal flu vaccine using a jet injector device is comparable to traditional needle and syringe delivery for eliciting an immune response.
- Trial name
- NCT01644149
- Testing
- Stratis Jet Injector, Needle and Syringe, 2011-2012 Fluzone trivalent inactivated influenza vaccine
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- PharmaJet, Inc.
Influenza
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control of a pandemic will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00309634
- Testing
- 4 adjuvanted pandemic influenza candidate vaccines, 4 non-adjuvanted pandemic influenza candidate vaccines
- Where
- Belgium
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home
We hypothesize that when offered influenza vaccine at little or no cost, in a setting where the value of the vaccine is connected to one's high risk child, vaccination rates for parents will approach 90-95%, similar to rates…
- Trial name
- NCT00812110
- Testing
- Influenzae vaccine
- Where
- United States
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Akron Children's Hospital
Chronic Obstructive Pulmonary Disease (COPD)
Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract
The colonization of potential pathogenic bacteria in lower respiratory tract is thought to be accountable for acute exacerbation in subjects with moderate to severe COPD.
- Trial name
- PAEAN (NCT03449459)
- Testing
- oral probiotics, aerosol inhaled amikacin, combined vaccination
- Where
- 3 sites in China
- Volunteers
- 144 people
- Sponsor
- Shanghai Zhongshan Hospital